Lupin launches Posaconazole delayed-release tablets for treating invasive fungal infections
Lupin Limited’s alliance partner, AET Pharma US Inc (a part of Tiefenbacher Group) has received an approval for its ANDA from United States Food & Drug Administration (USFDA). Post which, Lupin launched Posaconazole delayed-release tablets, 100 mg.
Posaconazole delayed-release tablets (100 mg) are the generic equivalent of Noxafil delayed-release tablets (100 mg) of Merck Sharp & Dohme Corp. These tablets are indicated for prophylaxis of invasive Aspergillus and Candida infections in patients, who are at a higher risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
As per the data provided by IQVIA MAT for December 2020, Posaconazole delayed-release tablets, 100 mg had estimated annual sales of USD 186 million in the US.
On the financial front, during December 2020 quarter, the company delivered 3 per cent QoQ growth in India formulations business and 4 per cent QoQ growth in the US business with continuous ramp up of Albuterol. In FY22, it plans to bring three products in the US namely, Albuterol, Perforomist, Brovana along with Fostair in Europe.
During Wednesday’s morning trading session, the stock of Lupin was trading lower by 2.1 per cent at Rs 1,073.20 from its previous close of Rs 1,095.80 on BSE.